Indeed, IL-10 and/or IL-6 signaling in ABC-DLBCL tumors regulate the malignant cell and tumor microenvironment (Wang et al., 2004; Lam et al., 2008b; Wang et al., 2014), suggesting that suppression of IL-10 and IL-6 secretion is beneficial for treating ABC-DLBCL. The gene discussed is IL6; the disease is diffuse large B-cell lymphoma.